A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer.
Please update your blog. This is first time cabo has been shown to work in patient with criz-resistance.
Thanks for the link. While we have evidence that cabo is effective for some ROS1 patients, apparently it’s very toxic with severe side effects, so it’s not a first-choice therapy for ROS1.
hello.Im japanese,contact you at first time.
my mother (59 years old, never smoked a cigaret) was diagnosed with lungcancer in april 2015, EGFR and ALK-negative.
So continued normal chemo.
Ros1+ was found in March 2016,and started ros1 clinical trial DS-6051b(Phase 1)from September 2016. but,it was not good result…
but ros1 Inhibitory is still our hope.
We want to join to search our hope and exchange information.